期刊文献+

New 14-mm diameter Niti-S biliary uncovered metal stent for unresectable distal biliary malignant obstruction 被引量:6

New 14-mm diameter Niti-S biliary uncovered metal stent for unresectable distal biliary malignant obstruction
在线阅读 下载PDF
导出
摘要 AIM To investigate whether an uncovered self-expandable metal stent(UCSEMS) with a large diameter could prevent recurrent biliary obstruction(RBO).METHODS Thirty-eight patients with malignant biliary obstruction underwent treatment with an UCSEMS with a 14-mm diameter(Niti-S 14). Retrospectively, we evaluated technical and functional success rate, RBO rate, time to RBO, survival time, and adverse events in these patients.RESULTS Stent placement success and functional success were achieved in all patients. Two patients(5.3%) had RBO due to tumor ingrowth or overgrowth. The median time to RBO was 190(range, 164-215) d. The median survival time was 120(range, 18-502) d. The 6-mo non-RBO rate was 91%. Other adverse events other than RBO occurred as follows: Acute cholecystitis, post-ERCP pancreatitis, hemobilia, and fever without exacerbation of liver injury, and liver abscess in 4(10.3%), 3(7.9%), 2(5.3%), 1(2.6%), and 1(2.6%), respectively. Migration of the stents was not observed.CONCLUSION Niti-S 14 is considered to be a preferable metal stent because of a low rate of RBO with no migration. AIM To investigate whether an uncovered self-expandable metal stent(UCSEMS) with a large diameter could prevent recurrent biliary obstruction(RBO).METHODS Thirty-eight patients with malignant biliary obstruction underwent treatment with an UCSEMS with a 14-mm diameter(Niti-S 14). Retrospectively, we evaluated technical and functional success rate, RBO rate, time to RBO, survival time, and adverse events in these patients.RESULTS Stent placement success and functional success were achieved in all patients. Two patients(5.3%) had RBO due to tumor ingrowth or overgrowth. The median time to RBO was 190(range, 164-215) d. The median survival time was 120(range, 18-502) d. The 6-mo non-RBO rate was 91%. Other adverse events other than RBO occurred as follows: Acute cholecystitis, post-ERCP pancreatitis, hemobilia, and fever without exacerbation of liver injury, and liver abscess in 4(10.3%), 3(7.9%), 2(5.3%), 1(2.6%), and 1(2.6%), respectively. Migration of the stents was not observed.CONCLUSION Niti-S 14 is considered to be a preferable metal stent because of a low rate of RBO with no migration.
出处 《World Journal of Gastrointestinal Endoscopy》 CAS 2018年第1期16-22,共7页 世界胃肠内镜杂志(英文版)(电子版)
关键词 Metal stent Malignant BILIARY OBSTRUCTION Pancreatic CANCER Migration Pancreatitis Bile duct CANCER OVERGROWTH Recurrent BILIARY OBSTRUCTION INGROWTH Adverse event Metal stent Malignant biliary obstruction Pancreatic cancer Migration Pancreatitis Bile duct cancer Overgrowth Recurrent biliary obstruction Ingrowth Adverse event
作者简介 Correspondence to:Masataka Kikuyama,MD,PhD,Department of Gastroenterology,Komagome Metropolitan Cancer and Infectious Diseases Center Komagome Hospital,3-15-22,Honkomagome,Bunnkyo-ku,Tokyo 113-8677,Japan.kikuyama110@cick.jp Telephone:+81-3-38232101 Fax:+81-3-38235433
  • 相关文献

同被引文献52

引证文献6

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部